Science 37 to Report First Quarter 2022 Financial Results on May 9, 2022

Rhea-AI Summary

Science 37 Holdings, Inc. (Nasdaq: SNCE) will report its first quarter 2022 financial results on May 9, 2022, before market opening. A conference call with management will occur at 5:00 a.m. PT / 8:00 a.m. ET, available via telephone and webcast. Science 37 specializes in decentralized clinical trials, aiming to enhance access and efficiency in clinical research through its Agile Clinical Trial Operating System. The company reports significant advancements in trial enrollment speed, participant retention, and diversity, which are integral to its operational model.

Positive

• Agile Clinical Trial Operating System enhances access to clinical research.
• Reports 15x faster enrollment and 28% better retention rates.
• Supports a 3x more diverse patient population.

Negative

• None.

RESEARCH TRIANGLE PARK, N.C., April 25, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report first quarter 2022 financial results before the market opens on Monday, May 9, 2022. Company management will host a corresponding conference call at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (844) 467-7754 for domestic callers or (270) 215-9366 for international callers, followed by Conference ID: 1388417. A live and archived webcast of the event will be available on the Investor Relations section of the Science 37 website at https://investors.science37.com/.

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 Agile Clinical Trial Operating System (OS) supports today’s more agile clinical research designs with its full stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 15x faster enrollment, 28% better retention and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation and data harmonization. For more information, visit https://www.science37.com.

Contacts:

MEDIA INQUIRIES:
Margie Kooman
Science 37
Phone: (984) 377-3737
Email: pr@science37.com

INVESTOR RELATIONS:
Caroline Paul
Gilmartin Group
investors@science37.com

FAQ

When will Science 37 report Q1 2022 financial results?

Science 37 will report its Q1 2022 financial results on May 9, 2022.

What is the purpose of the conference call on May 9, 2022?

The conference call will discuss the Q1 2022 financial results of Science 37.

What are the key features of Science 37's Agile Clinical Trial Operating System?

The Agile Clinical Trial Operating System enables faster enrollment, better retention, and a more diverse patient population.

How can investors access the conference call?

Investors can access the conference call by dialing (844) 467-7754 for domestic calls or (270) 215-9366 for international calls, using Conference ID: 1388417.